Toll Free: 1-888-928-9744

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016


Global Markets Direct's, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2016', provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects
- The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Leishmaniasis (Kala-Azar) Overview 10 Therapeutics Development 11 Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11 Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12 Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13 Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 15 Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Leishmaniasis (Kala-Azar) - Products under Development by Companies 19 Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 20 Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 21 Advinus Therapeutics Ltd. 21 Anacor Pharmaceuticals, Inc. 22 BioLingus AG 23 Dafra Pharma International Ltd. 24 iCo Therapeutics Inc. 25 ManRos Therapeutics 26 Matinas BioPharma Holdings, Inc. 27 Mologen AG 28 Nanomerics Ltd 29 Takeda Pharmaceutical Company Limited 30 Zydus Cadila Healthcare Limited 31 Leishmaniasis (Kala-Azar) - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 18-MC - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 amphotericin B - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 amphotericin B - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 amphotericin B - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 amphotericin B - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 CDRI-99/288 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 corifungin - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Indotecan hydrochloride - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 interferon gamma - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 KVH-14 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 leishmaniasis vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 leishmaniasis vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 leishmaniasis vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 leishmaniasis vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 MGN-1331 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 NPC-1161B - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Oleylphosphocholine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 P-MAPA - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Peptides for Infectious Diseases - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Polysaccharide for Oncology, Infectious Disease and Allergy - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 S-010269 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecule for Leishmaniasis - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecule for Leishmaniasis - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecule for Visceral Leishmaniasis - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecules for Infectious Diseases - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules for Leishmaniasis - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules for Leishmaniasis - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecules for Leishmaniasis - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Small Molecules for Protozoal Infections - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Small Molecules for Visceral Leishmaniasis - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecules for Visceral Leishmaniasis - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small molecules to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Synthetic Peptides for Infectious Disease - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 visceral leishmaniasis vaccine - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 87 Leishmaniasis (Kala-Azar) - Dormant Projects 91 Leishmaniasis (Kala-Azar) - Discontinued Products 93 Leishmaniasis (Kala-Azar) - Product Development Milestones 94 Featured News & Press Releases 94 Mar 22, 2016: Profounda launches Impavido (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States 94 Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 94 Sep 28, 2015: Knight Profounda U.S. Partner for Impavido 95 Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 95 Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 95 Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 96 Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis 97 Nov 11, 2013: Paladin Announces Extension of the Impavido® PDUFA Date by Three Months 97 Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 98 Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 98 Appendix 100 Methodology 100 Coverage 100 Secondary Research 100 Primary Research 100 Expert Panel Validation 100 Contact Us 100 Disclaimer 101
List of Tables
Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2016 11 Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H1 2016 21 Leishmaniasis (Kala-Azar) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 22 Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H1 2016 23 Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H1 2016 24 Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2016 25 Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H1 2016 26 Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 27 Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H1 2016 28 Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2016 29 Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 30 Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Number of Products by Stage and Target, H1 2016 34 Number of Products by Stage and Mechanism of Action, H1 2016 36 Number of Products by Stage and Route of Administration, H1 2016 38 Number of Products by Stage and Molecule Type, H1 2016 40 Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H1 2016 87 Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2016 91 Leishmaniasis (Kala-Azar) - Dormant Projects (Contd..1), H1 2016 92 Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2016 93

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.